Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1 1

Status

Completed 12Recruiting 5Unknown 4Not yet recruiting 2Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 26Prostatic Neoplasms 22Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 12Lung Neoplasms 11Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2Melanoma 2

Interventions

Oxaliplatin 10pembrolizumab 8Fluorouracil 8Leucovorin 7Paclitaxel 5Gemcitabine 5Docetaxel 5Capecitabine 5Cyclophosphamide 4Blood Specimen Collection 4zolbetuximab 3fludarabine 3cemiplimab 3Trastuzumab 3Taxes 3Ramucirumab 3Radiotherapy 3Radiosurgery 3Irinotecan 3trastuzumab deruxtecan 2enzalutamide 2durvalumab 2darolutamide 2Standard of Care 2Nivolumab 2Folfox protocol 2Dexamethasone 2Cisplatin 2130-nm albumin-bound paclitaxel 2tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Adenocarcinoma × Docetaxel × Clear all
NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Maia Biotechnology

Phase 3 Recruiting
300 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT04361708 2025-10-01

I-FLOAT

University of Chicago

Phase 1 Recruiting
54 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07018570 2025-08-26

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

National Cancer Center Hospital East

Phase 2 Recruiting
26 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT05264896 2023-09-07

Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Chinese University of Hong Kong

Phase 3 Recruiting
110 enrolled
Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡